Stereotaxis' $12.5 Million Direct Stock Offering
Stereotaxis, Inc. (NYSE: STXS), based in St. Louis, is at the forefront of advancing surgical robotics for minimally invasive procedures. In a major announcement, the company revealed it has entered into definitive agreements with a strategic industry partner and select institutional investors for a direct registered offering of common stock, aiming to raise approximately $12.5 million at a share price of $2.00. This significant financial move marks a vital phase in Stereotaxis' journey as it continues to innovate in the field of surgical robotics.
Purpose of the Offering
The proceeds from this offering are expected to solidify Stereotaxis' balance sheet and will predominantly be used to propel product commercialization and fuel extensive research and development efforts. According to David Fischel, the company's Chairman and CEO, this funding will greatly assist in navigating a milestone-rich year, ensuring that Stereotaxis continues to lead in providing unprecedented surgical solutions. "We appreciate the support of our strategic partner and institutional investors in this offering," he expressed, highlighting the collaborative effort behind this initiative.
Details of the Financing
Anticipated gross proceeds from the offering are expected to reach about $12.5 million before the deduction of placement agent fees and additional expenses related to the offering. The funding process includes an initial closing of approximately $8.5 million, which is anticipated to finalize soon. Following this, a second tranche worth $4 million is set to close in the coming months, subject to customary closing conditions. The exclusive placement agent for this endeavor is Lake Street Capital Markets LLC, ensuring that the offering is handled by a firm well-versed in facilitating such transactions.
Strategic Position in the Market
Stereotaxis operates within the dynamic landscape of surgical robotics, an area gaining traction amidst a technological revolution within healthcare. The company is renowned for its commitment to innovation, focusing on delivering enhanced robotic systems and solutions that support interventional procedures. This funding will allow Stereotaxis to extend its reach in developing technologies that help healthcare providers deliver safer and more efficient treatments to patients. With a record of treating over 150,000 patients worldwide, its technology is making significant strides across the surgical landscape.
About Stereotaxis
Founded with the vision of transforming surgical practices, Stereotaxis has emerged as a global leader in surgical robotics. Its mission revolves around developing robotic systems, instruments, and solutions specifically tailored for the interventional laboratory. Through its innovative technologies, Stereotaxis seeks to enhance patient care, ensuring procedures are conducted with the utmost precision and safety. As the company progresses, it remains committed to creating connections and promoting intelligence within operating rooms, effectively elevating the standard of care in medicine.
Frequently Asked Questions
What is the main goal of Stereotaxis' recent offering?
The primary goal is to strengthen the company's balance sheet while funding product commercialization and research initiatives.
How much capital is Stereotaxis aiming to raise?
Stereotaxis is looking to raise approximately $12.5 million through the direct stock offering.
Who is involved in the financing?
The financing is led by a strategic industry partner along with contributions from select institutional investors.
What role does Lake Street Capital Markets have in the offering?
Lake Street Capital Markets LLC serves as the exclusive placement agent responsible for facilitating the stock offering.
How has Stereotaxis impacted the field of surgery?
With its advanced robotic technologies, Stereotaxis has treated over 150,000 patients, significantly enhancing safety and efficiency in surgical procedures.
